辅助生殖技术受孕妊娠中游离胎儿DNA检测性能及胎儿分数估算不受影响
这项病例对照研究纳入21 558例连续妊娠(自然受孕15 707例,辅助生殖技术受孕5851例),比较两种受孕方式下胎儿分数估算和游离胎儿DNA检测信息率。结果显示辅助生殖技术受孕与自然受孕的胎儿分数中位数均为9.2%,受孕方式不影响胎儿分数或检测信息率。
要点
- 辅助生殖技术受孕与自然受孕的胎儿分数中位数均为9.2%,差异无统计学意义。
- 辅助生殖技术受孕组21三体高风险率0.7%低于自然受孕组1.3%(P=0.001)。
- 辅助生殖技术受孕组13三体和性染色体非整倍体假阳性率显著更高。
核心结论
- 受孕方式(辅助生殖技术 vs 自然)不影响胎儿分数估算或游离胎儿DNA检测信息率。
研究设计与样本
- 病例对照研究,纳入21 558例连续妊娠(自然受孕n=15 707,辅助生殖技术受孕n=5851),辅助生殖技术受孕按卵母细胞来源分层。
- 样本采集时间为2015年4月至2019年9月,孕妇来自全球不同中心,自妊娠第10周起采血。
- 采用大规模平行全基因组测序分析血浆游离胎儿DNA,因测序服务商技术变更使用单端和双端两种技术。
主要发现
- 单变量t检验显示辅助生殖技术受孕组胎儿分数中位数9.2%与自然受孕组9.2%无显著差异。
- 辅助生殖技术受孕组21三体高风险率0.7% vs 自然受孕组1.3%(P=0.001),18三体高风险率0.1% vs 0.3%(P=0.001)。
- 辅助生殖技术受孕组假阳性率显著更高,主要见于13三体(P=0.001)和性染色体非整倍体(P<0.001)。
- 多变量模型提示性染色体非整倍体差异由测序模式而非受孕方式导致,使用自身卵母细胞的辅助生殖技术受孕组13三体假阳性概率更高(P=0.004)。
关键数值与推荐
- 胎儿分数<2%或任何质量控制指标失败定义为无信息结果。
- 多变量分析显示受孕方式未强烈影响胎儿分数百分比。
- 按非整倍体类型分层的多变量模型提示21三体风险分类差异受卵母细胞来源影响(P<0.0001)。
临床怎么用
- 作者认为该信息对临床医生和遗传咨询师告知辅助生殖技术妊娠患者游离胎儿DNA检测的风险和局限性尤其有价值。
- 本研究显示辅助生殖技术受孕妊娠不被归类为产前检测高风险妊娠的概率并不更高。
局限性
- 本研究缺乏辅助生殖技术受孕和自然受孕低危及高危病例的随访数据,因此比较两组假阳性率的结果需谨慎解读。
- 收集不同辅助生殖技术方式及胚胎植入前非整倍体遗传学检测治疗的信息将有助于对本研究观察到的趋势得出明确解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does ART-based conception influence fetal fraction (FF) estimation and cell-free fetal DNA (cffDNA) testing performance? SUMMARY ANSWER: Mode of conception (ART versus natural) does not impact FF estimation or cffDNA test informativity rates. WHAT IS KNOWN ALREADY: Pregnancies achieved via ART are increasing, and cffDNA testing is displacing traditional prenatal screening methods due to its high sensitivity and specificity and noninvasive nature. However, conflicting data exist on cffDNA testing performance and FF in ART pregnancies compared with natural pregnancies. STUDY DESIGN, SIZE, DURATION: We performed a case-control study that included 21 558 consecutive pregnancies (spontaneous, n = 15 707; ART, n = 5851). ART-conceived pregnancies were stratified into two groups according to oocyte origin. Samples were collected from April 2015 to September 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included women from different centers worldwide. Blood samples were drawn from the 10th week of gestation onward. Massive parallel whole-genome sequencing was used to analyze cffDNA content in blood plasma. Two different types of technologies (single-end and paired-end) were applied because of analysis technology changes made by the sequencing provider over time. FF was determined using different methods depending on the type of technology used. Cases with an FF <2% or with failure in any quality control metrics were classified as noninformative. An analysis of covariance model was selected to identify which qualitative (sequencing methodology, mode of conception, type (i.e. multiplicity) of gestation and age (women >35 or <35 years old)) and quantitative (gestational age, BMI) variables were predictors of FF value. Multinomial logistic regression was used to evaluate whether the mode of conception impacted cffDNA testing performance. MAIN RESULTS AND THE ROLE OF CHANCE: A univariate t-test demonstrated no significant differences in FF values between ART (median FF = 9.2%) and spontaneous pregnancies (median FF = 9.2%). Also, a multivariate analysis showed that the mode of conception, did not strongly impact the percentage of FF. ART-treated women showed a lower incidence of high-risk cffDNA results compared to women who conceived naturally, specifically for trisomy (T)21 (0.7% versus 1.3%, P = 0.001) and T18 (0.1% versus 0.3%, P = 0.001). A multivariate model stratified by type of aneuploidy suggested that these differences were conditioned by oocyte origin, especially for the T21 risk classification (P < 0.0001). False-positive rates (FPRs) were significantly higher in the ART population, mainly for T13 (P = 0.001) and sexual chromosome aneuploidies (SCAs; P < 0.001). A multivariate model suggested that the differences observed in SCAs were caused by sequencing modality rather than by mode of conception. Likewise, ART-treated women who used their own oocytes had a higher probability of a false positive for T13 (P = 0.004). LIMITATIONS, REASONS FOR CAUTION: Our study lacks follow-up data for low- and high-risk cases of both ART-conceived and naturally conceived pregnancies. Therefore, the results comparing FPR in both populations should be interpreted carefully. Also, collecting information about different ART modalities and regarding preimplantation genetic testing for aneuploidy treatments would help draw definite explanations for the trends observed in this study. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study that demonstrates, with a large sample size, that FF is not influenced by mode of conception, demystifying the notion that patients undergoing ART have a higher probability of noninformative cffDNA testing results. Multivariate models stratified by oocyte origin and type of aneuploidy demonstrated that ART-conceived pregnancies do not have a higher probability of classification as a high-risk pregnancy in prenatal testing. This information is especially valuable to clinicians and genetic counselors when informing patients about the risks and limitations of cffDNA testing in ART pregnancies. STUDY FUNDING/COMPETING INTEREST(S): This study was financially supported by Igenomix Lab S.L.U. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Balaguer N, Mateu-Brull E, Gómez-López M, et al. Cell-free fetal DNA testing performance and fetal fraction estimation are not affected in ART-conceived pregnancies. Hum Reprod. 2022. PMID: 36223600. doi:10.1093/humrep/deac217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。